← All trials
NCT03356483
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 30, 2018
- Primary completion
- Jan 31, 2022
- Completion date
- Jul 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yale UniversityLead sponsor
- Yale UniversityReponsible party - principal investigator
- Yale UniversityOverall official - principal investigator
- Yale UniversityStudy director
- Heffter Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.